Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Health Canada approves lamivudine for treatment of chronic HBV

Dec. 2, 1998

AMBI seeks partners to develop oral nisin for H. pylori eradication

Dec. 2, 1998

Multiple clinical studies support efficacy and safety of HSR-237 in patients with IBS

Nov. 30, 1998

Ferring patents dual T-cell proliferation and protein farnesyltransferase inhibitors

Nov. 27, 1998

Potent and highly selective CCK-A antagonist designed by Tobishi

Nov. 26, 1998

New compounds for immunoinflammatory and neoplastic diseases in the pipeline at Ferring

Nov. 26, 1998

Shearwater Polymers will pegylate interferon alfa-2a for Roche under new agreement

Nov. 26, 1998

Major clinical trials demonstrate efficacy of Rebetron in chronic HCV infection

Nov. 23, 1998

Anti-H. pylori cephems in development at Takeda

Nov. 19, 1998

Lamivudine highlighted at recent Study for Liver Diseases meeting

Nov. 18, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...